<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-151532" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ocular Amyloidosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mathew</surname>
            <given-names>Raeba</given-names>
          </name>
          <aff>Canadian Specialist Hospital, Abu Hail, Dubai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zeppieri</surname>
            <given-names>Marco</given-names>
          </name>
          <aff>University Hospital of Udine, Italy</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Raeba Mathew declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marco Zeppieri declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-151532.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Amyloidosis is a heterogeneous group of disorders characterized by the deposition of an abnormal protein known as amyloid in various parts of the body, including the eyes and periocular structures.<xref ref-type="bibr" rid="article-151532.r1">[1]</xref> Amyloid, an insoluble fibrillary protein resulting from a dynamic misfolding process, aggregates in the intracellular and extracellular spaces of the body,&#x000a0;leading to progressive organ damage.</p>
      </sec>
      <sec id="article-151532.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>Amyloidosis&#x000a0;is classified&#x000a0;into systemic or localized forms.<xref ref-type="bibr" rid="article-151532.r1">[1]</xref>&#x000a0;This disease may occur as a primary condition or secondary to poorly controlled inflammatory diseases, such as chronic infections, autoimmune conditions, familial Mediterranean fever, and plasma cell dyscrasia, such as multiple myeloma.<xref ref-type="bibr" rid="article-151532.r2">[2]</xref><xref ref-type="bibr" rid="article-151532.r3">[3]</xref>&#x000a0;Based on the amyloid protein type, clinicians refer to the systemic disease as AL (amyloid immunoglobulin light chain), AA (amyloid A protein), or ATTR (amyloid transport protein transthyretin).<xref ref-type="bibr" rid="article-151532.r1">[1]</xref></p>
      </sec>
      <sec id="article-151532.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>AL amyloidosis is the most common form of systemic amyloidosis in the United States, with approximately 78% of new cases annually. The hereditary form of ATTR amyloidosis is a less common systemic condition, accounting for 10% to 20% of diagnosed cases in tertiary centers, and is more prevalent in men. AA amyloidosis is a rare acquired condition secondary to chronic inflammation, with an annual incidence of 6%.<xref ref-type="bibr" rid="article-151532.r4">[4]</xref></p>
        <p>Amyloidosis may involve the eye or ocular adnexa with high phenotypic variability. Ocular amyloidosis&#x000a0;is frequently attributed&#x000a0;to localized AL amyloidosis, accounting for 78.6% of cases, followed by systemic AL amyloidosis at 16.2% and multiple myeloma-associated AL amyloidosis at 10.7%.<xref ref-type="bibr" rid="article-151532.r2">[2]</xref>&#x000a0;Approximately 11.8% of patients with AL amyloidosis have ocular involvement, and in 5% of cases, ocular involvement is the initial presentation.<xref ref-type="bibr" rid="article-151532.r5">[5]</xref>&#x000a0;</p>
        <p>Ocular manifestations in AL amyloidosis are mostly extraocular, involving the orbit, conjunctiva, temporal artery, and extraocular muscles.<xref ref-type="bibr" rid="article-151532.r5">[5]</xref>&#x000a0;In hereditary forms of amyloidosis, such as non-transthyretin familial amyloidosis, the cornea is primarily affected, representing 20% of cases, while vitreous involvement occurs in 10% of cases in ATTR amyloidosis, with the retina being affected only rarely.<xref ref-type="bibr" rid="article-151532.r5">[5]</xref><xref ref-type="bibr" rid="article-151532.r6">[6]</xref>&#x000a0;Ocular involvement in secondary amyloidosis is rare.<xref ref-type="bibr" rid="article-151532.r5">[5]</xref>&#x000a0;Ocular orbital amyloidosis affects those who are between 45 and 65 years with no sex predilection.<xref ref-type="bibr" rid="article-151532.r7">[7]</xref>&#x000a0;In transthyretin amyloidosis, women experience ocular symptoms more frequently, representing 46% of cases, compared to men at 15%.<xref ref-type="bibr" rid="article-151532.r5">[5]</xref></p>
      </sec>
      <sec id="article-151532.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>In response to extracellular stimuli like low pH, oxidation, and high temperature, proteins synthesized in the endoplasmic reticulum undergo unfolding and misfolding.&#x000a0;Consequently, these proteins form monomers that aggregate to create amyloid fibrils, which deposit&#x000a0;across the body&#x000a0;in intra and extracellular tissues.&#x000a0;In hereditary amyloidosis, misfolding occurs due to a mutation in the protein structure that stimulates amyloid fibril formation. Amyloid fibrils cause tissue damage by various mechanisms such as alteration of tissue architecture, interaction with cell surface receptors, inflammation, oxidative stress, and activation of apoptosis. The amyloid may be deposited locally at the synthesis or distant sites, leading to tissue damage.<xref ref-type="bibr" rid="article-151532.r8">[8]</xref>&#x000a0;The deposit may manifest as neuropathy or vascular obstruction and increased vascular fragility. The mass effect of amyloid deposition may lead to structural distortion. Deposition in the vitreous cavity leads to media opacification.<xref ref-type="bibr" rid="article-151532.r9">[9]</xref></p>
      </sec>
      <sec id="article-151532.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The confirmatory test for amyloidosis is the presence of apple-green birefringence on Congo red staining on the biopsy specimen. Other features of amyloidosis are homogeneous granular, filamentous eosinophilic appearance in hematoxylin and eosin staining, metachromasia on crystal violet staining, and ultraviolet fluorescence on thioflavin T staining.<xref ref-type="bibr" rid="article-151532.r10">[10]</xref></p>
      </sec>
      <sec id="article-151532.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Various clinical presentations are observed based on the part of the eye affected.</p>
        <p>
<bold>Orbital Amyloidosis</bold>
</p>
        <p>Orbital involvement is more common in systemic AL amyloidosis or can occur as a part of localized amyloidosis, a rare condition that affects the head and neck. The latter may present in 2 forms. The most common clinical picture is a progressive proptosis with limitation of extraocular movements due to bilateral nodular infiltration of extraocular muscles and orbital adnexa. Rarely, this condition may present as an&#x000a0;amyloidoma&#x000a0;involving the anterior orbital area close to the lacrimal glands.<xref ref-type="bibr" rid="article-151532.r11">[11]</xref><xref ref-type="bibr" rid="article-151532.r12">[12]</xref>&#x000a0;Most commonly, amyloidosis occurs in the fourth to sixth decades of life and affects both sexes equally.<xref ref-type="bibr" rid="article-151532.r7">[7]</xref>&#x000a0;Amyloidosis may cause restrictive exophthalmoplegia, which can be mistaken for ocular&#x000a0;thyroidopathy, and an accurate diagnosis may require orbital imaging and thyroid function tests.</p>
        <p>Optic nerve involvement in amyloidosis usually results from amyloid masses in the orbital apex or due to dural infiltration leading to compressive optic neuropathy. Neuropathic amyloidosis usually spares the optic nerve.<xref ref-type="bibr" rid="article-151532.r13">[13]</xref>&#x000a0;Amyloidosis uncommonly involves the lacrimal gland and may present as a&#x000a0;hard, mobile mass in the upper temporal orbit that rarely attaches to the periocular bones. Amyloidosis may also be associated with eccentric proptosis. Bilateral involvement is common in systemic amyloidosis. An accurate diagnosis may require&#x000a0;excluding&#x000a0;similar conditions such as vascular malformations, dacryoadenitis, or lacrimal gland neoplasms.<xref ref-type="bibr" rid="article-151532.r14">[14]</xref>&#x000a0;AL amyloidosis may present a clinical picture similar to temporal arteritis with bilateral vision loss due to amyloid light chain infiltration of the temporal artery. A temporal artery biopsy confirms the diagnosis of AL amyloid.<xref ref-type="bibr" rid="article-151532.r15">[15]</xref>&#x000a0;Patients with AL amyloidosis may also develop spontaneous bilateral purplish discoloration around the eyelids and the surrounding area. This symptom is usually a late sign caused by increased vascular fragility resulting from the deposition of misfolded light-chain fragments.<xref ref-type="bibr" rid="article-151532.r2">[2]</xref></p>
        <p>Conjunctival amyloidosis can affect healthy people of any age or gender and may cause nodular or diffuse deposits on the bulbar or tarsal conjunctiva. The tarsal amyloid deposits on the upper eyelids can lead to ptosis, while bulbar amyloidosis commonly affects the superior fornices. Amyloid deposits may be unilateral or bilateral and have a firm, waxy appearance with color varying from yellow, pink, or salmon patches. In some cases, recurrent subconjunctival hemorrhages may occur due to increased capillary fragility caused by amyloid deposits. Other conditions, such as lymphoproliferative deposits and conjunctival inflammatory granuloma, must be ruled out. Excision biopsy and a characteristic histopathology result can confirm the diagnosis.<xref ref-type="bibr" rid="article-151532.r16">[16]</xref>&#x000a0;Conjunctival amyloidosis may be an early indication of systemic amyloidosis; hence, systemic evaluation and follow-up are necessary.</p>
        <p>
<bold>Corneal Amyloidosis</bold>
</p>
        <p>Corneal involvement in amyloidosis&#x000a0;may occur as a primary localized condition&#x000a0;or as a part of the systemic disease. Primary localized corneal amyloidosis has 2 distinct inherited forms: gelatinous drop-like corneal dystrophy and lattice corneal dystrophy types I and III. Meretoja syndrome is the main form of primary systemic amyloidosis that presents with lattice corneal dystrophy type II.<xref ref-type="bibr" rid="article-151532.r17">[17]</xref>&#x000a0;Secondary localized corneal amyloidosis is present in various ocular diseases such as trichiasis, trachoma, sarcoidosis, interstitial keratitis, phlyctenular keratitis, uveitis, chronic post-traumatic inflammation, glaucoma, or keratoconus. However, secondary systemic amyloidosis typically spares the cornea.</p>
        <p>Gelatinous drop-like corneal dystrophy is a rare autosomal recessive condition that mainly affects the Asian population, particularly Japanese individuals. Gelatinous drop-like corneal dystrophy usually presents within the first and second decades and is a slowly progressive condition. Nodular amyloid deposits initially involve the subepithelial part of the cornea and later coalesce to form mulberry-like opacities extending to the stroma. Nodular amyloid deposits lead to photophobia, foreign body sensation, and impaired vision. Despite attempting various surgical modalities, recurrence remains a significant challenge, leading to a poor prognosis.<xref ref-type="bibr" rid="article-151532.r18">[18]</xref></p>
        <p>Lattice dystrophy type I, also known as Biber-Haab-Dimmer corneal dystrophy, is a bilateral disease with autosomal dominant inheritance, albeit asymmetrical. Biber-Haab-Dimmer corneal dystrophy most commonly affects people in the&#x000a0;western&#x000a0;world, with few reports from Japan. At the end of the first decade of life, Biber-Haab-Dimmer corneal dystrophy usually presents with ocular irritation due to recurrent corneal erosions and decreased vision. These opacities usually appear denser anteriorly and centrally but typically spare the peripheral cornea. The progressive condition leads to significant visual impairment by the fourth to sixth decade.<xref ref-type="bibr" rid="article-151532.r19">[19]</xref>&#x000a0;Lattice dystrophy type III is an autosomal recessive disease that presents after the fourth decade of life, leading to visual impairment by the seventh decade of life.<xref ref-type="bibr" rid="article-151532.r19">[19]</xref></p>
        <p>Lattice corneal dystrophy type II, or the gelsolin type, is an autosomal dominant form of systemic amyloidosis, previously called familial amyloidotic polyneuropathy type IV, Finnish type. Lattice corneal dystrophy type II is a rare condition initially reported in Finland. A few cases have also been detected worldwide in Europe, North America, and India.<xref ref-type="bibr" rid="article-151532.r2">[2]</xref><xref ref-type="bibr" rid="article-151532.r20">[20]</xref>&#x000a0;This condition is part of Meretoja syndrome, which includes the typical triad of lattice corneal dystrophy, progressive bilateral cranial neuropathy characterized by facial palsy, mild sensory peripheral neuropathy, walking difficulties, dysarthria, drooling, loose skin resulting in a mask-like face, protruding lips, and dry skin. Ocular symptoms manifest after the third decade of life, primarily&#x000a0;as&#x000a0;dry eyes. Vision typically remains preserved until the seventh decade. The condition affects both sexes, although women exhibit an earlier onset and more severe involvement than men. Patients with this disease are at increased risk of open-angle glaucoma. Facial paralysis and skin laxity affect eyelid closure and cause ectropion, leading to exposure keratitis.<xref ref-type="bibr" rid="article-151532.r21">[21]</xref></p>
        <p>
<bold>Vitreoretinal Amyloidosis</bold>
</p>
        <p>Vitreous amyloidosis&#x000a0;is a rare condition associated with familial amyloidotic polyneuropathy&#x000a0;(FAP), which can occur in hereditary or sporadic non-hereditary forms. Mutations in the transthyretin gene cause FAP, the most common form of hereditary amyloidosis, transmitted in an autosomal dominant manner.<xref ref-type="bibr" rid="article-151532.r22">[22]</xref>&#x000a0;The liver mainly synthesizes transthyretin. However, transthyretin can also be produced by the brain's retinal pigment epithelium and choroid plexus. Ocular involvement&#x000a0;is reported&#x000a0;in 10% of patients with ATTR amyloidosis.<xref ref-type="bibr" rid="article-151532.r2">[2]</xref>&#x000a0;While FAP commonly occurs in Western populations, instances of vitreous amyloidosis with distinct TTR mutations also emerge in India and China.<xref ref-type="bibr" rid="article-151532.r23">[23]</xref><xref ref-type="bibr" rid="article-151532.r24">[24]</xref></p>
        <p>Vitreous opacities are usually bilateral but may be asymmetric. They can appear as cobwebs, sheets, crystalline needle-like structures, veils, or strings of pearls. Visual symptoms vary from glare, floaters, and mild to severe visual impairment depending on the density of opacities (see<bold>&#x000a0;Image.&#x000a0;</bold>Vitreous Amyloidosis). These vitreous opacities typically extend from the peripheral vitreous in a centripetal manner. Vitreous opacities abutting the posterior lens capsule may form footplates or pseudopodia lentis (see<bold>&#x000a0;Image.&#x000a0;</bold>Pseudopodia Lentis in Vitreous Amyloidosis).</p>
        <p>In FAP, the incidence of vitreous opacity varies from 5.4% to 35%.<xref ref-type="bibr" rid="article-151532.r23">[23]</xref>&#x000a0;Vitreous opacities can be an isolated sign of amyloidosis or associated with other signs such as amyloid deposits on the iris, pupillary margin, choroidal infiltration, and glaucoma.<xref ref-type="bibr" rid="article-151532.r25">[25]</xref>&#x000a0;Retinal perivascular amyloid deposits can appear as focal plaques, tortuosity, beading, or vascular sheathing. Retinal hemorrhages and cotton wool spots may be seen in 20% of patients with hereditary TTR amyloidosis, leading to a higher incidence of retinal vein occlusions.<xref ref-type="bibr" rid="article-151532.r6">[6]</xref>&#x000a0;Retinal amyloid angiopathy and choroidal amyloid angiopathy have also been described.<xref ref-type="bibr" rid="article-151532.r26">[26]</xref></p>
      </sec>
      <sec id="article-151532.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Although the clinical features may suggest ocular amyloidosis, the definitive diagnosis is through a biopsy of the lesion and a histopathology evaluation.&#x000a0;Surgeons may take an excision biopsy from lesions of the conjunctiva, eyelid, lacrimal gland, or temporal artery. Additionally, vitreous samples obtained from vitrectomy can help diagnose the condition. In an orbital mass, a biopsy via the superior lateral sulcus may be necessary to confirm the diagnosis of&#x000a0;amyloidoma&#x000a0;and rule out other conditions, such as a lymphoproliferative disorder.<xref ref-type="bibr" rid="article-151532.r27">[27]</xref>&#x000a0;The histopathology examination shows the characteristic appearance, which helps to confirm the diagnosis of amyloidosis.<xref ref-type="bibr" rid="article-151532.r10">[10]</xref></p>
        <p>Computed tomography scans are usually more informative than magnetic resonance imaging (MRI) in assessing periocular and orbital amyloidosis due to their higher sensitivity in detecting bone changes and calcifications in tissues. The mass effect may cause global displacement. Orbital amyloidosis may exhibit extraocular muscle enlargement, soft tissue infiltration or mass, and calcification. Extraocular muscle shows highly irregular nodular or fusiform enlargement with areas of calcification. Muscle involvement may be unilateral or bilateral, which usually spares the tendons.<xref ref-type="bibr" rid="article-151532.r13">[13]</xref><xref ref-type="bibr" rid="article-151532.r28">[28]</xref><xref ref-type="bibr" rid="article-151532.r29">[29]</xref><xref ref-type="bibr" rid="article-151532.r30">[30]</xref>&#x000a0;However, MRI provides a more accurate anatomical definition of the extension of the lesion.<xref ref-type="bibr" rid="article-151532.r31">[31]</xref></p>
        <p>In vitreoretinal amyloidosis, fundus fluorescein angiography may show retinal vascular occlusion and focal or diffuse leakage&#x000a0;that is more prominent in the posterior pole than the retinal periphery.<xref ref-type="bibr" rid="article-151532.r32">[32]</xref>&#x000a0;Optical coherence tomography in eyes with veil-like vitreous opacities shows needle-shaped deposits on the retinal surface that extend to the vitreous cavity.<xref ref-type="bibr" rid="article-151532.r33">[33]</xref>&#x000a0;When amyloid has been found in a site-specific for localized amyloidosis, screening for amyloid in another site of the body, such as subcutaneous fat or bone marrow, with a tissue biopsy is recommended. Ancillary tests to rule out systemic involvement include a complete blood count, peripheral blood smear, liver and renal function tests, prothrombin time, beta-microglobulin assay, serum immunofixation electrophoresis with measurement of the free light chain, bone marrow aspiration, urine electrophoresis, chest x-ray, electrocardiogram, echocardiography, and ultrasonography of the abdomen.<xref ref-type="bibr" rid="article-151532.r27">[27]</xref></p>
      </sec>
      <sec id="article-151532.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Upon diagnosing&#x000a0;the disease,&#x000a0;it is mandatory to assess&#x000a0;for systemic involvement. Observation is advisable in asymptomatic or mildly symptomatic patients with localized amyloidosis. In extensive conjunctival infiltration, close follow-up is vital as surgical excision or other interventions are&#x000a0;not effectiveineffective.<xref ref-type="bibr" rid="article-151532.r13">[13]</xref>&#x000a0;Surgical&#x000a0;debulking&#x000a0;is &#x000a0;indicated&#x000a0;for&#x000a0;patients&#x000a0;experiencing&#x000a0;symptomatic diseases&#x000a0;such as ocular motility disturbances, compressive optic neuropathy, and unacceptable cosmetic appearance. In patients with medical contraindications for surgery or with extensive infiltrative disease, radiotherapy with or without surgical debulking may be useful. Close follow-up of the patients is necessary&#x000a0;forto&#x000a0;the prevention ofprevent&#x000a0;complications.<xref ref-type="bibr" rid="article-151532.r28">[28]</xref>&#x000a0;Cryotherapy&#x000a0;may be effective for conjunctival amyloidosis as it disrupts the blood supply to the amyloid deposits. Surgical debulking before cryotherapy is advisable as it allows access to freezing to the deeper blood supply.<xref ref-type="bibr" rid="article-151532.r34">[34]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-151532.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Lacrimal gland involvement can mimic lymphoproliferative disorders, vascular malformations, dacryoadenitis, or lacrimal gland neoplasms.<xref ref-type="bibr" rid="article-151532.r14">[14]</xref>&#x000a0;A computed tomography scan helps assess bone invasion or calcification. A definitive diagnosis is made by biopsy and histopathology evaluation.&#x000a0;Focal orbital amyloidosis mimics are pseudotumor, lymphoproliferative lesion, sarcoidosis, or cavernous hemangioma. Characteristic findings on computed tomography and MRI differentiate these conditions.<xref ref-type="bibr" rid="article-151532.r35">[35]</xref><xref ref-type="bibr" rid="article-151532.r36">[36]</xref><xref ref-type="bibr" rid="article-151532.r37">[37]</xref></p>
        <p>Corneal amyloidosis may mimic other forms of corneal dystrophies.<xref ref-type="bibr" rid="article-151532.r38">[38]</xref>&#x000a0;Other&#x000a0;differential diagnoses include various causes of monoclonal gammopathy, lecithin-cholesterol-acyltransferase deficiency, Fabry disease, cystinosis, tyrosine transaminase deficiency, systemic lysosomal storage diseases such as mucopolysaccharidoses, lipidoses, mucolipidoses, and several skin diseases known as X-linked ichthyosis, and keratosis follicularis.&#x000a0;The main differentials of vitreoretinal amyloidosis are intermediate uveitis of infectious or non-infectious etiology, masquerades such as intra-ocular lymphoma, and multiple sclerosis.<xref ref-type="bibr" rid="article-151532.r39">[39]</xref>&#x000a0;After ruling out&#x000a0;various causes for vitritis, histopathology of the vitrectomy samples helps to confirm the diagnosis.</p>
      </sec>
      <sec id="article-151532.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>
<bold>Orbital amyloidosis</bold>
</p>
        <p>The prognosis of orbital amyloidosis depends on the extent of involvement and the area affected. Observing asymptomatic patients is an option, while surgical debulking of the mass may be necessary in symptomatic cases. Excision treatment may continue by cryotherapy to treat residual infiltrating tissue, but incomplete removal of the conjunctival infiltration may result in frequent recurrences.<xref ref-type="bibr" rid="article-151532.r40">[40]</xref>&#x000a0;Resection of the levator palpebrae muscle is rarely required, even in ptosis and globe displacement.<xref ref-type="bibr" rid="article-151532.r41">[41]</xref>&#x000a0;External beam radiotherapy may benefit patients where complete surgical debulking or excision cannot avoid or reduce the risk of recurrence.<xref ref-type="bibr" rid="article-151532.r27">[27]</xref></p>
        <p>
<bold>Corneal amyloidosis</bold>
</p>
        <p>Corneal dystrophy type I presents with visual symptoms by&#x000a0;10&#x000a0;years of age, leading to marked visual impairment by 40 to 60 years of age. In type III corneal dystrophy, visual symptoms manifest after 40 years of age, and vision&#x000a0;is impaired&#x000a0;after 60 years of age. Both conditions are progressive, and there is no therapy to prevent progressive visual impairment. Surgeons most commonly treat corneal opacities with deep anterior lamellar keratoplasty. However, recurrence and stromal graft rejection remain possible complications. Penetrating keratoplasty may also be of value in these cases. An overall graft survival rate of 100% at 12 years has been reported.<xref ref-type="bibr" rid="article-151532.r42">[42]</xref></p>
        <p>There is no curative treatment for patients with Meretoja syndrome. Visual symptoms typically begin before 25 years of age, but individuals usually retain reasonably good visual acuity up to 65 years of age. Early intervention to control dry eye may help to alleviate symptoms. In patients with recurrent corneal ulcers and corneal scarring leading to corneal opacification, keratoplasty is necessary. However, the visual outcome after traditional penetrating keratoplasty is usually poor because of frequent postoperative complications related to dry eye and corneal anesthesia, persistent epithelial defects, and the ongoing deposition of amyloid in the transplanted cornea.<xref ref-type="bibr" rid="article-151532.r21">[21]</xref></p>
        <p>In gelatinous drop-like corneal dystrophy, visual symptoms present&#x000a0;before 10 years of age, with marked visual impairment at 10 to 30 years of age. Penetrating keratoplasty, deep lamellar keratoplasty, or superficial keratectomy&#x000a0;may help to achieve visual rehabilitation, although early post-surgical relapses have been reported.<xref ref-type="bibr" rid="article-151532.r21">[21]</xref><xref ref-type="bibr" rid="article-151532.r18">[18]</xref></p>
        <p>
<bold>Vitreoretinal amyloidosis</bold>
</p>
        <p>Pars plana vitrectomy usually clears media haze and significantly improves visual acuity in vitreoretinal amyloidosis. However, recurrence may occur in 25% of patients&#x000a0;due to&#x000a0;retrolental residual vitreous, persistent intraocular production of amyloid fibrils by the retinal pigment epithelium, or both.<xref ref-type="bibr" rid="article-151532.r23">[23]</xref>&#x000a0;Repeated vitrectomy may be&#x000a0;necessary in these specific cases.</p>
      </sec>
      <sec id="article-151532.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Based on the part of the eye affected, complications vary and include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Orbital or ocular adnexal amyloidosis.</p>
          </list-item>
          <list-item>
            <p>Ptosis, eyelid swelling, proptosis, lid or conjunctival masses, ophthalmoplegia, and paresis of accommodation.</p>
          </list-item>
          <list-item>
            <p>Amyloid deposition in trabecular meshwork can lead to glaucoma.</p>
          </list-item>
          <list-item>
            <p>Corneal amyloidosis.</p>
          </list-item>
          <list-item>
            <p>Keratoconjunctivitis sicca, corneal opacification, and severe visual loss.</p>
          </list-item>
          <list-item>
            <p>Vitreoretinal disorders.</p>
          </list-item>
          <list-item>
            <p>ATTR amyloidosis causes significant visual defects due to dense vitreous opacities.<xref ref-type="bibr" rid="article-151532.r2">[2]</xref><xref ref-type="bibr" rid="article-151532.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-151532.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Educating patients diagnosed with ocular amyloidosis about the potential systemic implications of the disease is essential. Patients should consult with an internist and other physicians as needed. Emphasize the importance of regular follow-up appointments with both physicians and ophthalmologists.</p>
      </sec>
      <sec id="article-151532.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Ocular amyloidosis&#x000a0;can occur as a localized condition or as part of systemic amyloidosis. AL amyloidosis and familial non-TTR or TTR amyloidosis may be associated with ocular complications. Ocular features may be the initial presentation or appear after the systemic condition diagnosis. AL amyloidosis is also known to cause severe neuropathy, myopathy, nephropathy, cardiomyopathy, or vasculopathy.</p>
        <p>Once detecting ocular amyloidosis, healthcare providers should refer patients for a thorough evaluation by the internist. In addition, patients with unexplained ocular findings&#x000a0;and a diagnosis of conditions such as &#x000a0;Waldenstrom macroglobulinemia and multiple myeloma should undergo a systemic workup. Patients presenting with corneal lattice dystrophy also need systemic evaluation.<xref ref-type="bibr" rid="article-151532.r2">[2]</xref>&#x000a0;</p>
        <p>Interprofessional management, including a team of internists, oncologists, hematologists, nephrologists, cardiologists, and neurologists working with ophthalmologists, helps optimal patient management.&#x000a0;Early diagnosis is necessary for treatment options such as chemotherapy and bone marrow transplant to mitigate the severity of the condition.<xref ref-type="bibr" rid="article-151532.r43">[43]</xref></p>
      </sec>
      <sec id="article-151532.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=151532&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=151532">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/ocular-amyloidosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=151532">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/151532/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=151532">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-151532.s15">
        <fig id="article-151532.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Pseudopodia Lentis in Vitreous Amyloidosis Reproduced with kind permission from Elsevier. Source publication: Venkatesh P, Selvan H, Singh SB, et al. Vitreous Amyloidosis: Ocular, Systemic, and Genetic Insights. Ophthalmology. 2017;124(7):1014-1022. doi:10.1016/j.ophtha.2017.03.011</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="amyloidosis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-151532.s16">
        <fig id="article-151532.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Vitreous Amyloidosis. Fundus color photo of an eye with vitreous amyloidosis Reproduced with kind permission from Elsevier, Source publication: Venkatesh P, Selvan H, Singh SB, et al. Vitreous Amyloidosis: Ocular, Systemic, and Genetic Insights. Ophthalmology. 2017;124(7):1014-1022. doi:10.1016/j.ophtha.2017.03.011</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="amyloid" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-151532.s17">
        <title>References</title>
        <ref id="article-151532.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sipe</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Buxbaum</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saraiva</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Westermark</surname>
                <given-names>P</given-names>
              </name>
              <collab>Nomenclature Committee of the International Society of Amyloidosis</collab>
            </person-group>
            <article-title>Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis.</article-title>
            <source>Amyloid</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>167</fpage>
            <page-range>167-70</page-range>
            <pub-id pub-id-type="pmid">23113696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dammacco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lisch</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kivel&#x000e4;</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Giancipoli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vacca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dammacco</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Amyloidosis and Ocular Involvement: an Overview.</article-title>
            <source>Semin Ophthalmol</source>
            <year>2020</year>
            <month>Jan</month>
            <day>02</day>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-26</page-range>
            <pub-id pub-id-type="pmid">31829761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lachmann</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Gilbertson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gallimore</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Sabin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Gillmore</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>PN</given-names>
              </name>
            </person-group>
            <article-title>Natural history and outcome in systemic AA amyloidosis.</article-title>
            <source>N Engl J Med</source>
            <year>2007</year>
            <month>Jun</month>
            <day>07</day>
            <volume>356</volume>
            <issue>23</issue>
            <fpage>2361</fpage>
            <page-range>2361-71</page-range>
            <pub-id pub-id-type="pmid">17554117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bustamante</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Zaidi</surname>
                <given-names>SRH</given-names>
              </name>
            </person-group>
            <chapter-title>Amyloidosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">29261990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reynolds</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Veverka</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Gertz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zeldenrust</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pulido</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>OCULAR MANIFESTATIONS OF SYSTEMIC AMYLOIDOSIS.</article-title>
            <source>Retina</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>1371</fpage>
            <page-range>1371-1376</page-range>
            <pub-id pub-id-type="pmid">29068915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minnella</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rissotto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Antoniazzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Di Girolamo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luigetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maceroni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bacherini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Falsini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Obici</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Ocular Involvement in Hereditary Amyloidosis.</article-title>
            <source>Genes (Basel)</source>
            <year>2021</year>
            <month>Jun</month>
            <day>22</day>
            <volume>12</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">34206500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Banerjee</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alam</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Subramanian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kundu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Poonam</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Orbital and adnexal amyloidosis: Thirty years experience at a tertiary eye care center.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2021</year>
            <month>May</month>
            <volume>69</volume>
            <issue>5</issue>
            <fpage>1161</fpage>
            <page-range>1161-1166</page-range>
            <pub-id pub-id-type="pmid">33913851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ikura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Endo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kitakata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Moriyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Jun</month>
            <day>06</day>
            <volume>23</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">35683015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Singhal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>AX</given-names>
              </name>
              <name>
                <surname>Dhingra</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ocular complications of plasma cell dyscrasias.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>1786</fpage>
            <page-range>1786-1800</page-range>
            <pub-id pub-id-type="pmid">36760117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sipe</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Buxbaum</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saraiva</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Westermark</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis.</article-title>
            <source>Amyloid</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>221</fpage>
            <page-range>221-4</page-range>
            <pub-id pub-id-type="pmid">25263598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murdoch</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Moseley</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Pepys</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Garner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Primary localised amyloidosis of the orbit.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1996</year>
            <month>Dec</month>
            <volume>80</volume>
            <issue>12</issue>
            <fpage>1083</fpage>
            <page-range>1083-6</page-range>
            <pub-id pub-id-type="pmid">9059275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jamshidi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Levi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rivera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mahoney</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Eberhart</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathologic and Proteomic Analysis of Amyloidomas Involving the Ocular Surface and Adnexa.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2022</year>
            <month>Apr</month>
            <day>01</day>
            <volume>157</volume>
            <issue>4</issue>
            <fpage>620</fpage>
            <page-range>620-627</page-range>
            <pub-id pub-id-type="pmid">34698334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taban</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>See</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Sadun</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Quiros</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Review: orbital amyloidosis.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>162</fpage>
            <page-range>162-5</page-range>
            <pub-id pub-id-type="pmid">15083087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Segado Mart&#x000ed;nez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruiz Garc&#x000ed;a</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abenza Baeza</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Amyloidosis localized in lacrimal gland.</article-title>
            <source>Med Clin (Barc)</source>
            <year>2022</year>
            <month>Aug</month>
            <day>12</day>
            <volume>159</volume>
            <issue>3</issue>
            <fpage>e23</fpage>
            <page-range>e23-e24</page-range>
            <pub-id pub-id-type="pmid">35643772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rubino</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Macaluso</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gandolfi</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Light-chain amyloidosis mimicking giant cell arteritis in a bilateral anterior ischemic optic neuropathy case.</article-title>
            <source>BMC Ophthalmol</source>
            <year>2013</year>
            <month>Dec</month>
            <day>20</day>
            <volume>13</volume>
            <fpage>82</fpage>
            <pub-id pub-id-type="pmid">24359546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suesskind</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ziemssen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rohrbach</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Conjunctival amyloidosis -- clinical and histopathologic features.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>253</volume>
            <issue>8</issue>
            <fpage>1377</fpage>
            <page-range>1377-83</page-range>
            <pub-id pub-id-type="pmid">25619666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carrwik</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stenevi</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Lattice corneal dystrophy, gelsolin type (Meretoja's syndrome).</article-title>
            <source>Acta Ophthalmol</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>87</volume>
            <issue>8</issue>
            <fpage>813</fpage>
            <page-range>813-9</page-range>
            <pub-id pub-id-type="pmid">19832730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaza</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barik</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Gelatinous drop-like corneal dystrophy: a review.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>101</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-15</page-range>
            <pub-id pub-id-type="pmid">27913443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Milovanova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gomon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rocha</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Classic lattice corneal dystrophy: a brief review and summary of treatment modalities.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>262</volume>
            <issue>6</issue>
            <fpage>1667</fpage>
            <page-range>1667-1681</page-range>
            <pub-id pub-id-type="pmid">37934291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maramattom</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Chickabasaviah</surname>
                <given-names>YT</given-names>
              </name>
            </person-group>
            <article-title>A new Indian family affected by gelsolin amyloidosis.</article-title>
            <source>Neurol India</source>
            <year>2013</year>
            <season>Nov-Dec</season>
            <volume>61</volume>
            <issue>6</issue>
            <fpage>673</fpage>
            <page-range>673-5</page-range>
            <pub-id pub-id-type="pmid">24441349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casal</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Monteiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abreu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Neves</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Beir&#x000e3;o</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Meretoja's Syndrome: Lattice Corneal Dystrophy, Gelsolin Type.</article-title>
            <source>Case Rep Med</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>2843417</fpage>
            <pub-id pub-id-type="pmid">28250773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adams</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ando</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Beir&#x000e3;o</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Coelho</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gertz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gillmore</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Lousada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Suhr</surname>
                <given-names>OB</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.</article-title>
            <source>J Neurol</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>268</volume>
            <issue>6</issue>
            <fpage>2109</fpage>
            <page-range>2109-2122</page-range>
            <pub-id pub-id-type="pmid">31907599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Venkatesh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Selvan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kashyap</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Temkar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gogia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vohra</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Vitreous Amyloidosis: Ocular, Systemic, and Genetic Insights.</article-title>
            <source>Ophthalmology</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>124</volume>
            <issue>7</issue>
            <fpage>1014</fpage>
            <page-range>1014-1022</page-range>
            <pub-id pub-id-type="pmid">28412068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title><italic>TTR</italic> Gly83Arg Mutation: Beyond Familial Vitreous Amyloidosis.</article-title>
            <source>Front Neurol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>821003</fpage>
            <pub-id pub-id-type="pmid">35185758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pathak-Ray</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pulpa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Blyth</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Vitreous amyloidosis and secondary glaucoma-a case report.</article-title>
            <source>Eye (Lond)</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>492</fpage>
            <page-range>492-4</page-range>
            <pub-id pub-id-type="pmid">12101461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kusaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pavesio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Khalid</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Keane</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Pulido</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>ASSOCIATION BETWEEN CHOROIDAL CHARACTERISTICS AND SYSTEMIC SEVERITY IN AMYLOIDOSIS.</article-title>
            <source>Retina</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>1037</fpage>
            <page-range>1037-1046</page-range>
            <pub-id pub-id-type="pmid">32826787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mora-Horna</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Rojas-Padilla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Guzm&#x000e1;n</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ceriotto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salcedo</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Ocular adnexal and orbital amyloidosis: a case series and literature review.</article-title>
            <source>Int Ophthalmol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>281</fpage>
            <page-range>281-98</page-range>
            <pub-id pub-id-type="pmid">26466598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leibovitch</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Selva</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Saeed</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McCann</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>McNab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rootman</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Periocular and orbital amyloidosis: clinical characteristics, management, and outcome.</article-title>
            <source>Ophthalmology</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>113</volume>
            <issue>9</issue>
            <fpage>1657</fpage>
            <page-range>1657-64</page-range>
            <pub-id pub-id-type="pmid">16828514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamidi Asl</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Liepnieks</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Nunery</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Yazaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Kappa III immunoglobulin light chain origin of localized orbital amyloidosis.</article-title>
            <source>Amyloid</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>179</fpage>
            <page-range>179-83</page-range>
            <pub-id pub-id-type="pmid">15523920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yerli</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aydin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Avci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haberal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Oto</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Focal Amyloidosis of the Orbit Presenting as a Mass: MRI and CT Features.</article-title>
            <source>Iran J Radiol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>241</fpage>
            <page-range>241-4</page-range>
            <pub-id pub-id-type="pmid">23329948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bartolomei</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ambrosini-Spaltro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salvi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Agati</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leonardi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Amyloidoma Involving the Orbit, Meckel's Cave and Infratemporal Fossa: 3T MRI Findings.</article-title>
            <source>Neuroradiol J</source>
            <year>2009</year>
            <month>Mar</month>
            <day>23</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-7</page-range>
            <pub-id pub-id-type="pmid">24206952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kakihara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hirano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kitahara</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miyahara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>OCULAR ANGIOGRAPHIC FEATURES IN JAPANESE PATIENTS WITH VAL30MET HEREDITARY TRANSTHYRETIN AMYLOIDOSIS.</article-title>
            <source>Retina</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>210</fpage>
            <page-range>210-215</page-range>
            <pub-id pub-id-type="pmid">34483312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kakihara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hirano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miyahara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Deposits on Retinal Surface Seen on OCT in Ocular Amyloidosis.</article-title>
            <source>Ophthalmol Retina</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>10</issue>
            <fpage>1005</fpage>
            <page-range>1005-1008</page-range>
            <pub-id pub-id-type="pmid">33422693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fraunfelder</surname>
                <given-names>FW</given-names>
              </name>
            </person-group>
            <article-title>Liquid nitrogen cryotherapy for conjunctival amyloidosis.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2009</year>
            <month>May</month>
            <volume>127</volume>
            <issue>5</issue>
            <fpage>645</fpage>
            <page-range>645-8</page-range>
            <pub-id pub-id-type="pmid">19433714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Korogi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hotta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shimomura</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kitajima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Negi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Orbital pseudotumors: value of short inversion time inversion-recovery MR imaging.</article-title>
            <source>Radiology</source>
            <year>1997</year>
            <month>Jan</month>
            <volume>202</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-9</page-range>
            <pub-id pub-id-type="pmid">8988192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simon</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Zoarski</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Rothman</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Numaguchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zagardo</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Mathis</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Systemic sarcoidosis with bilateral orbital involvement: MR findings.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>1998</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>336</fpage>
            <page-range>336-7</page-range>
            <pub-id pub-id-type="pmid">9504490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thorn-Kany</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arru&#x000e9;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Delisle</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Lacroix</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lagarrigue</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Manelfe</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Cavernous hemangiomas of the orbit: MR imaging.</article-title>
            <source>J Neuroradiol</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>79</fpage>
            <page-range>79-86</page-range>
            <pub-id pub-id-type="pmid">10444931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klintworth</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Corneal dystrophies.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2009</year>
            <month>Feb</month>
            <day>23</day>
            <volume>4</volume>
            <fpage>7</fpage>
            <pub-id pub-id-type="pmid">19236704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Touhami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leclercq</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stanescu-Segall</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Touitou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bodaghi</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Differential Diagnosis of Vitritis in Adult Patients.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2021</year>
            <month>May</month>
            <day>19</day>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>786</fpage>
            <page-range>786-795</page-range>
            <pub-id pub-id-type="pmid">34003716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prager</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Habib</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Gambogi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Busam</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Marr</surname>
                <given-names>BP</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Follow-Up of 4 Patients with Conjunctival Amyloidosis.</article-title>
            <source>Ocul Oncol Pathol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>313</fpage>
            <page-range>313-317</page-range>
            <pub-id pub-id-type="pmid">30320104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eneh</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kratky</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Primary localized orbital amyloid: case report and literature review; 2004-2015.</article-title>
            <source>Can J Ophthalmol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>e131</fpage>
            <page-range>e131-e136</page-range>
            <pub-id pub-id-type="pmid">27521683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ono</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishiyama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hayashidera</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nejima</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Miyata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Amano</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Twelve-year follow-up of penetrating keratoplasty.</article-title>
            <source>Jpn J Ophthalmol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>131</fpage>
            <page-range>131-136</page-range>
            <pub-id pub-id-type="pmid">27885526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151532.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palladini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Current treatment of AL amyloidosis.</article-title>
            <source>Haematologica</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>94</volume>
            <issue>8</issue>
            <fpage>1044</fpage>
            <page-range>1044-8</page-range>
            <pub-id pub-id-type="pmid">19644136</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
